Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram

Daniel Keizman, Maya Gottfried, Maya Ish-Shalom, Natalie Maimon, Avivit Peer, Avivit Neumann, Eli Rosenbaum, Svetlana Kovel, Roberto Pili, Victoria Sinibaldi, Michael A Carducci, Hans Hammers, Mario Eisenberger, Avishay Sella

Research output: Contribution to journalArticle

Abstract

Background. The neutrophil-to-lymphocyte ratio (NLR), an inflammation marker, is prognostic in several cancers. We assessed the association between the pretreatment NLR and outcome of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the CYP17 inhibitor ketoconazole. Methods. This was an international, retrospective study of 156 mCRPC patients treated with ketoconazole. The independent effect of the pretreatment NLR and factors associated with treatment outcome were determined by multivariate analysis. Results. Seventy-eight patients (50%) had a ≥50% decline in prostate-specific antigen (PSA). The median progression-free survival (PFS) time was 8 months. Excluded from the analysis were 23 patients without available data on their NLR and those with a recent health event or treatment associated with a blood count change. Sixty-two patients (47%) had a pretreatment NLR >3. Risk factors associated with the PFS outcome were a pretreatment NLR >3 and PSA doubling time (PSADT)

Original languageEnglish (US)
Pages (from-to)1508-1514
Number of pages7
JournalOncologist
Volume17
Issue number12
DOIs
StatePublished - 2012

Fingerprint

Nomograms
Ketoconazole
Castration
Prostatic Neoplasms
Neutrophils
Lymphocytes
Prostate-Specific Antigen
Disease-Free Survival
Steroid 17-alpha-Hydroxylase
Multivariate Analysis
Retrospective Studies
Inflammation
Health
Neoplasms

Keywords

  • Ketoconazole treatment
  • Metastatic castration-resistant prostate cancer
  • Neutrophil-to-lymphocyte ratio
  • Outcome
  • Predictive nomogram

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole : Association with outcome and predictive nomogram. / Keizman, Daniel; Gottfried, Maya; Ish-Shalom, Maya; Maimon, Natalie; Peer, Avivit; Neumann, Avivit; Rosenbaum, Eli; Kovel, Svetlana; Pili, Roberto; Sinibaldi, Victoria; Carducci, Michael A; Hammers, Hans; Eisenberger, Mario; Sella, Avishay.

In: Oncologist, Vol. 17, No. 12, 2012, p. 1508-1514.

Research output: Contribution to journalArticle

Keizman, Daniel ; Gottfried, Maya ; Ish-Shalom, Maya ; Maimon, Natalie ; Peer, Avivit ; Neumann, Avivit ; Rosenbaum, Eli ; Kovel, Svetlana ; Pili, Roberto ; Sinibaldi, Victoria ; Carducci, Michael A ; Hammers, Hans ; Eisenberger, Mario ; Sella, Avishay. / Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole : Association with outcome and predictive nomogram. In: Oncologist. 2012 ; Vol. 17, No. 12. pp. 1508-1514.
@article{8740f48234f34747b34e450306bf186e,
title = "Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram",
abstract = "Background. The neutrophil-to-lymphocyte ratio (NLR), an inflammation marker, is prognostic in several cancers. We assessed the association between the pretreatment NLR and outcome of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the CYP17 inhibitor ketoconazole. Methods. This was an international, retrospective study of 156 mCRPC patients treated with ketoconazole. The independent effect of the pretreatment NLR and factors associated with treatment outcome were determined by multivariate analysis. Results. Seventy-eight patients (50{\%}) had a ≥50{\%} decline in prostate-specific antigen (PSA). The median progression-free survival (PFS) time was 8 months. Excluded from the analysis were 23 patients without available data on their NLR and those with a recent health event or treatment associated with a blood count change. Sixty-two patients (47{\%}) had a pretreatment NLR >3. Risk factors associated with the PFS outcome were a pretreatment NLR >3 and PSA doubling time (PSADT)",
keywords = "Ketoconazole treatment, Metastatic castration-resistant prostate cancer, Neutrophil-to-lymphocyte ratio, Outcome, Predictive nomogram",
author = "Daniel Keizman and Maya Gottfried and Maya Ish-Shalom and Natalie Maimon and Avivit Peer and Avivit Neumann and Eli Rosenbaum and Svetlana Kovel and Roberto Pili and Victoria Sinibaldi and Carducci, {Michael A} and Hans Hammers and Mario Eisenberger and Avishay Sella",
year = "2012",
doi = "10.1634/theoncologist.2012-0125",
language = "English (US)",
volume = "17",
pages = "1508--1514",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "12",

}

TY - JOUR

T1 - Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole

T2 - Association with outcome and predictive nomogram

AU - Keizman, Daniel

AU - Gottfried, Maya

AU - Ish-Shalom, Maya

AU - Maimon, Natalie

AU - Peer, Avivit

AU - Neumann, Avivit

AU - Rosenbaum, Eli

AU - Kovel, Svetlana

AU - Pili, Roberto

AU - Sinibaldi, Victoria

AU - Carducci, Michael A

AU - Hammers, Hans

AU - Eisenberger, Mario

AU - Sella, Avishay

PY - 2012

Y1 - 2012

N2 - Background. The neutrophil-to-lymphocyte ratio (NLR), an inflammation marker, is prognostic in several cancers. We assessed the association between the pretreatment NLR and outcome of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the CYP17 inhibitor ketoconazole. Methods. This was an international, retrospective study of 156 mCRPC patients treated with ketoconazole. The independent effect of the pretreatment NLR and factors associated with treatment outcome were determined by multivariate analysis. Results. Seventy-eight patients (50%) had a ≥50% decline in prostate-specific antigen (PSA). The median progression-free survival (PFS) time was 8 months. Excluded from the analysis were 23 patients without available data on their NLR and those with a recent health event or treatment associated with a blood count change. Sixty-two patients (47%) had a pretreatment NLR >3. Risk factors associated with the PFS outcome were a pretreatment NLR >3 and PSA doubling time (PSADT)

AB - Background. The neutrophil-to-lymphocyte ratio (NLR), an inflammation marker, is prognostic in several cancers. We assessed the association between the pretreatment NLR and outcome of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the CYP17 inhibitor ketoconazole. Methods. This was an international, retrospective study of 156 mCRPC patients treated with ketoconazole. The independent effect of the pretreatment NLR and factors associated with treatment outcome were determined by multivariate analysis. Results. Seventy-eight patients (50%) had a ≥50% decline in prostate-specific antigen (PSA). The median progression-free survival (PFS) time was 8 months. Excluded from the analysis were 23 patients without available data on their NLR and those with a recent health event or treatment associated with a blood count change. Sixty-two patients (47%) had a pretreatment NLR >3. Risk factors associated with the PFS outcome were a pretreatment NLR >3 and PSA doubling time (PSADT)

KW - Ketoconazole treatment

KW - Metastatic castration-resistant prostate cancer

KW - Neutrophil-to-lymphocyte ratio

KW - Outcome

KW - Predictive nomogram

UR - http://www.scopus.com/inward/record.url?scp=84871598079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871598079&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2012-0125

DO - 10.1634/theoncologist.2012-0125

M3 - Article

C2 - 22971522

AN - SCOPUS:84871598079

VL - 17

SP - 1508

EP - 1514

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 12

ER -